# United Therapeutics share price today (United Therapeutics Corporation, UTHR)

> United Therapeutics Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. UTHR · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/uthr

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Slowing from a peak, from the last 12 quarters
- Price: $601.32 (+35.0% in a year)
- P/E: 21.5× (higher than 100% of the last 4.6 years)
- Revenue (Jun 2026): $783 M (−1.9% on a year ago)
- Profit (Jun 2026): $333 M (+7.6% on a year ago)
- Operating margin: 42.2% (−6.2 points on a year ago)
- ROE: 19%, FY25
- ROIC: 31.3%, against a 6.9% cost of capital: +24.4 points

Biggest thing to watch: the P/E is higher than 100% of its own history, so the multiple has already done part of the work. ## What is the United Therapeutics share price today? United Therapeutics Corporation's share price was $601.32 at the close on 3 November 2026. It has been rising for 6 weeks. That is 12.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $449 and $601, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row. Over the last 10 years the share price moved +441% while the S&P 500 moved +255%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does United Therapeutics pay? United Therapeutics Corporation pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is United Therapeutics on? United Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is United Therapeutics profitable? United Therapeutics Corporation earned $333 M of net profit in the Jun 2026 quarter, +7.6% on the same quarter a year earlier. Full-year FY25 profit was $1.3 B. Over 4 years profit has grown 29.4% a year on average. That is 42.5% of the quarter's revenue. The same quarter a year earlier earned $310 M. For the full year, FY25 profit was $1.3 B (+11.7% on the year before). Why profit moved: revenue changed −1.9% on a year earlier and the margin moved −6.2 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +5.8% and revenue +2.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does United Therapeutics make, and is it growing? United Therapeutics Corporation reported $783 M of revenue in the Jun 2026 quarter, −1.9% on the same quarter a year earlier. Over 4 years it has grown 17.2% a year on average. The last full year, FY25, came in at $3.2 B. The last four reported quarters add to $3.2 B. FY25 revenue was $3.2 B, +10.6% on the year before. Recent pace: the last four quarters grew +2.7% on average, against 17.2% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +2.5%, against +9.8% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +5.5%, against +10.7% a year (rolling over). ## How much of every $100 of sales does United Therapeutics keep? United Therapeutics Corporation's operating margin was 42.2% in the Jun 2026 quarter, 6.2 percentage points lower than the same quarter a year ago. Across 5 years it has been between 40.8% and 51.1%. The latest quarter is within that range. Why the margin moved: operating margin changed −6.2 percentage points on the year while gross margin changed −1.7 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is United Therapeutics' profit turning into cash? Over the last 3 years, 110% of United Therapeutics Corporation's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $1.6 B of operating cash against $1.3 B of profit. After $521 M of spending on assets, $1.0 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does United Therapeutics' cash go? United Therapeutics Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $997 M on assets over the last 3 years. Averaged over those years that is 10.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $997 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is United Therapeutics' P/E ratio, and how does it compare with its own history? United Therapeutics Corporation's P/E is 21.5×, about the highest it has ever been. Its usual P/E (the middle reading) is 15.4×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +13.1% while the price moved +35.0%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +38.9% a year; about +15.5% a year came from earnings growth and about +23.4 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the United Therapeutics business getting better or worse? United Therapeutics Corporation's business is slowing from a peak. Revenue and profit growth have slowed sharply (revenue growth from +25.0% at its peak to +2.5% now), while ROCE is still 20.1%. This is based on 12 quarters of 4 measures. Why it matters: slowing from a peak is where good stories often end quietly. ## How much does United Therapeutics earn on its capital? United Therapeutics Corporation earned a ROE of 19% in FY25. That is up from a low of 12% in FY21. Its return on capital used (ROIC) is 24.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 41.9% net margin and 0.40× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 41.9% net margin × 0.40× asset turnover × 1.11× leverage (assets divided by equity) ≈ 18.6% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 31.3% − 6.9% = +24.4 percentage points. The 6.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. ## Does United Therapeutics have too much debt? United Therapeutics Corporation has total debt of $37.6 M against shareholder equity of $7.1 B as of Dec 2025, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.20 in FY21 to 0.01 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the United Therapeutics shareholding pattern? 6.3% of United Therapeutics Corporation's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 2.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is United Therapeutics from balance-sheet trouble? For United Therapeutics Corporation, the Z-score is 18.19. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 18.19 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does United Therapeutics rank in its industry? 55.2 out of 100, rank 10 of 28 in Drug Manufacturers - Specialty & Generic, with 81% of the evidence available. United Therapeutics Corporation scores 55.2 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 10. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 14.3 + 20 + 9.2 + 11.7 = 55.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is United Therapeutics compared with? United Therapeutics ranks 10 of 28 Drug Manufacturers - Specialty & Generic companies on the 4-Factor Sector Score, with 55.2 out of 100. 1. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) NBIX · turning · Most evidence points up · 81% evidence 66.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 34.4% · Profit 100% · Operating margin change 1 points · 83% evidence Capital efficiency 17.8/25 · ROCE 19.3% · Operating margin 22.2% · 76% evidence Valuation 13.8/20 · P/E 24× · PEG 0.71 · 65% evidence Relative strength 9.2/20 · Lead over its industry -4.9% · Lead over S&P 500 7% · 1 year 8.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25.8 + 17.8 + 13.8 + 9.2 = 66.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Eton Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/eton) ETON · leader · Most evidence points up · 64% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 81% · Profit n/a · Operating margin change 37.2 points · 62% evidence Capital efficiency 17.6/25 · ROCE 29.2% · Operating margin 35.8% · 76% evidence Valuation 8.8/20 · P/E 78.2× · PEG n/a · 15% evidence Relative strength 14.0/20 · Lead over its industry 37.9% · Lead over S&P 500 52.3% · 1 year 201.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.3 + 17.6 + 8.8 + 14 = 65.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Indivior Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/indv) INDV · quiet · Evidence leans up · 71% evidence 63.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.5/35 · Revenue 13.5% · Profit 100% · Operating margin change 23.4 points · 83% evidence Capital efficiency 20.8/25 · ROCE 152.3% · Operating margin 46.9% · 76% evidence Valuation 10.3/20 · P/E 14.1× · PEG n/a · 15% evidence Relative strength 4.9/20 · Lead over its industry -13% · Lead over S&P 500 -2.1% · 1 year 15.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.5 + 20.8 + 10.3 + 4.9 = 63.5 · What this means: Earnings are strong; relative strength in its sector is -13% and the one-year return is 15.8%. 4. [Kiniksa Pharmaceuticals International, plc](https://www.sectoralpha.in/us/stocks/knsa) KNSA · leader · Evidence leans up · 71% evidence 61.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 58.7% · Profit 100% · Operating margin change -1.7 points · 83% evidence Capital efficiency 11.9/25 · ROCE 13.8% · Operating margin 11.2% · 76% evidence Valuation 9.0/20 · P/E 61× · PEG n/a · 15% evidence Relative strength 17.0/20 · Lead over its industry 40.9% · Lead over S&P 500 56.9% · 1 year 143.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23.8 + 11.9 + 9 + 17 = 61.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Xeris Biopharma Holdings, Inc.](https://www.sectoralpha.in/us/stocks/xers) XERS · leader · Evidence leans up · 64% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 36.2% · Profit n/a · Operating margin change -0.7 points · 62% evidence Capital efficiency 11.5/25 · ROCE 16.5% · Operating margin 5.6% · 76% evidence Valuation 8.7/20 · P/E 83.3× · PEG n/a · 15% evidence Relative strength 18.6/20 · Lead over its industry 18.4% · Lead over S&P 500 32.5% · 1 year 39.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.7 + 11.5 + 8.7 + 18.6 = 59.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch Health Companies Inc.](https://www.sectoralpha.in/us/stocks/bhc) BHC · leader · Evidence leans up · 71% evidence 59.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 10.1% · Profit -1220.4% · Operating margin change 9.1 points · 83% evidence Capital efficiency 12.6/25 · ROCE 13.5% · Operating margin 27.2% · 76% evidence Valuation 10.9/20 · P/E -1.7× · PEG n/a · 15% evidence Relative strength 18.3/20 · Lead over its industry 15.4% · Lead over S&P 500 29.8% · 1 year 22.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.5 + 12.6 + 10.9 + 18.3 = 59.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [BioCryst Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/bcrx) BCRX · quiet · Evidence leans up · 64% evidence 58.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 68.5% · Profit n/a · Operating margin change 26.9 points · 62% evidence Capital efficiency 18.1/25 · ROCE 112% · Operating margin 45.1% · 76% evidence Valuation 11.0/20 · P/E -6.6× · PEG n/a · 15% evidence Relative strength 4.5/20 · Lead over its industry -13.8% · Lead over S&P 500 -3.2% · 1 year 20.9% · 100% evidence · 3 of 12 weeks ahead Exact sum: 25.3 + 18.1 + 11 + 4.5 = 58.9 · What this means: Earnings are strong; relative strength in its sector is -13.8% and the one-year return is 20.9%. 8. [Amneal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amrx) AMRX · leader · Evidence leans up · 71% evidence 58.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 9.3% · Profit 100% · Operating margin change 2.8 points · 83% evidence Capital efficiency 14.8/25 · ROCE 17.1% · Operating margin 18.3% · 76% evidence Valuation 9.3/20 · P/E 35.1× · PEG n/a · 15% evidence Relative strength 13.1/20 · Lead over its industry 14.1% · Lead over S&P 500 27.5% · 1 year 77.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21 + 14.8 + 9.3 + 13.1 = 58.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Phibro Animal Health Corporation](https://www.sectoralpha.in/us/stocks/pahc) PAHC · breaking out · Evidence leans up · 81% evidence 58.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 17.2% · Profit 100% · Operating margin change 0.3 points · 83% evidence Capital efficiency 14.9/25 · ROCE 16.4% · Operating margin 10.6% · 76% evidence Valuation 11.8/20 · P/E 12.8× · PEG 1.44 · 65% evidence Relative strength 7.3/20 · Lead over its industry -22.7% · Lead over S&P 500 -13% · 1 year -14% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.1 + 14.9 + 11.8 + 7.3 = 58.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. United Therapeutics Corporation this page UTHR · turning · Evidence leans up · 81% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.3/35 · Revenue 2.5% · Profit 5.6% · Operating margin change -6.2 points · 83% evidence Capital efficiency 20.0/25 · ROCE 21.2% · Operating margin 42.2% · 76% evidence Valuation 9.2/20 · P/E 17.5× · PEG 1.92 · 65% evidence Relative strength 11.7/20 · Lead over its industry -2.7% · Lead over S&P 500 9.4% · 1 year 34% · 100% evidence · 3 of 12 weeks ahead Exact sum: 14.3 + 20 + 9.2 + 11.7 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Liquidia Corporation](https://www.sectoralpha.in/us/stocks/lqda) LQDA · quiet · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative
12. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) VTRS · breaking out · Evidence leans up · 64% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Trulieve Cannabis Corp.](https://www.sectoralpha.in/us/stocks/trlv) TRLV · breaking out · Evidence leans up · 64% evidence 50.9 out of 100 Growth Capital Valuation Relative
14. [ANI Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/anip) ANIP · basing · Evidence leans up · 64% evidence 50.2 out of 100 Growth Capital Valuation Relative
15. [Teva Pharmaceutical Industries Limited](https://www.sectoralpha.in/us/stocks/teva) TEVA · leader · Evidence leans down · 64% evidence 48.0 out of 100 Growth Capital Valuation Relative
16. [Zoetis Inc.](https://www.sectoralpha.in/us/stocks/zts) ZTS · turning · Evidence leans down · 81% evidence 46.8 out of 100 Growth Capital Valuation Relative
17. [Haleon plc](https://www.sectoralpha.in/us/stocks/hln) HLN · quiet · Too little evidence to rank firmly · 56% evidence 45.8 out of 100 Growth Capital Valuation Relative
18. [Perrigo Company plc](https://www.sectoralpha.in/us/stocks/prgo) PRGO · breaking out · Evidence leans down · 64% evidence 45.1 out of 100 Growth Capital Valuation Relative
19. [Elanco Animal Health Incorporated](https://www.sectoralpha.in/us/stocks/elan) ELAN · turning · Evidence leans down · 71% evidence 43.9 out of 100 Growth Capital Valuation Relative
20. [Lantheus Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lnth) LNTH · turning · Evidence leans down · 81% evidence 43.6 out of 100 Growth Capital Valuation Relative
21. [Alkermes plc](https://www.sectoralpha.in/us/stocks/alks) ALKS · quiet · Evidence leans down · 81% evidence 43.4 out of 100 Growth Capital Valuation Relative
22. [HUTCHMED (China) Limited](https://www.sectoralpha.in/us/stocks/hcm) HCM · breaking out · Too little evidence to rank firmly · 51% evidence 39.8 out of 100 Growth Capital Valuation Relative
23. [Prestige Consumer Healthcare Inc.](https://www.sectoralpha.in/us/stocks/pbh) PBH · quiet · Evidence leans down · 71% evidence 35.1 out of 100 Growth Capital Valuation Relative
24. [Alvotech](https://www.sectoralpha.in/us/stocks/alvo) ALVO · breaking out · Most evidence points down · 71% evidence 33.1 out of 100 Growth Capital Valuation Relative
25. [Hims & Hers Health, Inc.](https://www.sectoralpha.in/us/stocks/hims) HIMS · quiet · Most evidence points down · 71% evidence 27.6 out of 100 Growth Capital Valuation Relative
26. [Supernus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/supn) SUPN · quiet · Most evidence points down · 71% evidence 26.6 out of 100 Growth Capital Valuation Relative
27. [Amylyx Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amlx) AMLX · leader · Too little evidence to rank firmly · 40% evidence 48.7 out of 100 Growth Capital Valuation Relative
28. Regencell Bioscience Holdings Limited RGC · breaking out · Too little evidence to rank firmly · 47% evidence 31.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Drug Manufacturers - Specialty & Generic](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic), all 28 compared on one page. ## Which companies are close to United Therapeutics in size? United Therapeutics is the 5th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Teva Pharmaceutical Industries, Haleon plc and Zoetis Inc. Just below it: Viatris Inc., Neurocrine Biosciences, Inc. and Elanco Animal Health Incorporated. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Teva Pharmaceutical Industries Limited](https://www.sectoralpha.in/us/stocks/teva) $48.8 billion
2. [Haleon plc](https://www.sectoralpha.in/us/stocks/hln) $38.8 billion
3. [Zoetis Inc.](https://www.sectoralpha.in/us/stocks/zts) $34.3 billion
4. United Therapeutics Corporation $25.8 billion
5. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) $21.7 billion
6. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) $16.8 billion
7. [Elanco Animal Health Incorporated](https://www.sectoralpha.in/us/stocks/elan) $12.3 billion

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Trip.com Group Limited](https://www.sectoralpha.in/us/stocks/tcom) $25.8 billion · Travel Services
2. [HP Inc.](https://www.sectoralpha.in/us/stocks/hpq) $25.6 billion · Computer Hardware
3. United Therapeutics Corporation $25.6 billion
4. [Baidu, Inc.](https://www.sectoralpha.in/us/stocks/bidu) $25.4 billion · Internet Content & Information
5. [InterContinental Hotels Group PLC](https://www.sectoralpha.in/us/stocks/ihg) $25.3 billion · Lodging

## What else do people ask about United Therapeutics? ### What were United Therapeutics's latest quarterly results? United Therapeutics Corporation reported revenue of $783 M and net profit of $333 M for the Jun 2026 quarter. Revenue fell 1.9% and profit rose 7.6% compared with a year earlier. Earnings per share were $7.27. The operating margin was 42.2%, 6.2 percentage points lower than a year earlier (as of 3 November 2026). ### What is United Therapeutics's market cap? United Therapeutics Corporation's market capitalisation is $25.8 B at a stock price of $601.32. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is United Therapeutics performing? United Therapeutics Corporation's share price has been rising for 6 weeks. In its latest quarter, revenue fell 1.9% and profit rose 7.6% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 3 weeks running (as of 3 November 2026). ### Will United Therapeutics's stock price go up? This page does not forecast United Therapeutics Corporation's stock price. What it shows instead: the stock price is $601.32, and it has been rising for 6 weeks. Its P/E of 21.5× is higher than 100% of its own last 5 years (as of 3 November 2026). ### Where is United Therapeutics in its business cycle? United Therapeutics Corporation's FY25 operating margin was 47.7%, against a 5-year range of 40.8% to 51.1%: the middle of its own range, neither a peak nor a low. The latest quarter was 42.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the United Therapeutics story? Biggest thing to watch: the P/E is higher than 100% of its own history, so the multiple has already done part of the work. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is United Therapeutics a stock worth studying right now? What the numbers show: United Therapeutics Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.